How does ASLT.Y's PE Ratio compare to its peers?

ASLT.Y is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the peer average (23.3x).

How does ASLT.Y's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

ASLT.Y is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the US Pharmaceuticals industry average (16.9x).

What is ASLT.Y's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ASLT.Y's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of ASLT.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ASLT.Y ($3.2) is trading below our estimate of [[fair value]] ($3.64)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

ASLT.Y Stock Overview

Asymchem Laboratories (Tianjin) Co., Ltd. More details

ASLT.Y fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	2/6

Rewards

Trading at 12.2% below our estimate of its fair value

Earnings are forecast to grow 29.95% per year

Risk Analysis

Shares are highly illiquid

Profit margins (13.8%) are lower than last year (31.7%)

Dividend of 2.3% is not well covered by free cash flows

My Notes

Capture your thoughts, links and company narrative

Asymchem Laboratories (Tianjin) Co., Ltd. Competitors

Prestige Consumer Healthcare

NYSE:PBH

US$3.9b

Organon

NYSE:OGN

US$3.7b

Elanco Animal Health

NYSE:ELAN

US$5.8b

Corcept Therapeutics

NasdaqCM:CORT

US$5.4b

Price History & Performance

Summary of share price highs, lows and changes for Asymchem Laboratories (Tianjin)
Historical stock prices
Current Share Price	CN¥3.20
52 Week High	CN¥3.20
52 Week Low	CN¥3.20
Beta	0.14
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	ASLT.Y	US Pharmaceuticals	US Market
7D	0%	-2.0%	-3.5%
1Y	n/a	7.6%	22.1%

Return vs Industry: Insufficient data to determine how ASLT.Y performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ASLT.Y performed against the US Market.

Price Volatility

Is ASLT.Y's price volatile compared to industry and market?
ASLT.Y volatility
ASLT.Y Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ASLT.Y's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ASLT.Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1998	9,300	Hao Hong	www.asymchem.com.cn

Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers process development and optimization, analytical services, and scale-up services for small molecule drug products throughout the pre-clinical and clinical stage; and ton-scale manufacturing services for registered starting materials, advanced intermediates, and active pharmaceutical ingredients. It also engages in pre-formulation and formulation development; chemical macromolecule contract development manufacture organization (CMDO) solutions for polypeptides, oligonucleotides, glycans, toxins-linkers and other macromolecules; biosynthesis solutions; biologics CDMO solutions for monoclonal antibodies and antibody-drug conjugates; and contract research organization solutions and messenger RNA solution.

Asymchem Laboratories (Tianjin) Co., Ltd. Fundamentals Summary

How do Asymchem Laboratories (Tianjin)'s earnings and revenue compare to its market cap?
ASLT.Y fundamental statistics
Market cap	US$3.84b
Earnings (TTM)	US$105.65m
Revenue (TTM)	US$765.38m

36.1x

P/E Ratio

5.0x

P/S Ratio

Is ASLT.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ASLT.Y income statement (TTM)
Revenue	CN¥5.57b
Cost of Revenue	CN¥3.24b
Gross Profit	CN¥2.33b
Other Expenses	CN¥1.56b
Earnings	CN¥769.03m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	2.17
Gross Margin	41.86%
Net Profit Margin	13.80%
Debt/Equity Ratio	0%

How did ASLT.Y perform over the long term?

See historical performance and comparison

Dividends

2.3%

Current Dividend Yield

83%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/16 02:16
End of Day Share Price	2024/09/18 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Asymchem Laboratories (Tianjin) Co., Ltd. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Bo Li	BofA Global Research
Yue Gao	Changjiang Securities Co. LTD.
Hao Wu	Chasing Securities

Asymchem Laboratories (Tianjin) OTCPK:ASLT.Y Stock Report